Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects

Trial Profile

Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2016

At a glance

  • Drugs KDT 501 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors KinDex Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jan 2016 Last checked against Clinicaltrials.gov record.
    • 28 Dec 2015 According to ClinicalTrials.gov record, status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top